Results 171 to 180 of about 387,731 (304)

A comparison by mismatch repair status of real‐world characteristics and outcomes in patients with stage II/III rectal cancer in the Netherlands

open access: yesInternational Journal of Cancer, Volume 158, Issue 4, Page 963-976, 15 February 2026.
What's new? Mismatch repair deficiency (dMMR) in rectal cancer is rare, and knowledge about tumor biological behavior, response to treatment, and clinical outcomes in this subset of patients is limited. This nationwide cohort study including 182 patients with dMMR rectal cancer found that they were younger and had more poorly differentiated tumors ...
Renee A. Lunenberg   +14 more
wiley   +1 more source

Personalized Models of Biological Barriers and Their Diseases: Recent Progress with Organs‐On‐Chips

open access: yesAdvanced Biology, Volume 10, Issue 2, February 2026.
Buck and Bugter et al. explore the architectural diversity and physiological functions of human barrier systems and reveal how organ‐on‐chip platforms, particularly those integrating patient‐derived cells, are advancing barrier disease modeling. They highlight how emerging biological and technological advances can be used to bridge the gap between ...
Franziska Buck   +4 more
wiley   +1 more source

A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series

open access: yesCancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Hepatoid adenocarcinoma (HAC) is a rare extrahepatic tumor of non‐germ cell origin that morphologically resembles hepatocellular carcinoma (HCC). HAC has a propensity to metastasize to the liver and therefore may be mistaken for HCC. There is a lack of standardized treatment protocols, and further studies are needed to evaluate the benefit of ...
Christina Liava   +4 more
wiley   +1 more source

Comparative Effectiveness and Modality‐Dependent Prognostic Value of Pathological Response Following Neoadjuvant Therapy for Locally Advanced Gastric Cancer

open access: yesCancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Neoadjuvant therapies, including chemotherapy (NACT), chemoradiotherapy (NACRT), and chemoimmunotherapy (NACIT), are standard for locally advanced gastric cancer (LAGC). Pathological response is a key surrogate for treatment effectiveness, but its correlation with long‐term outcomes across modalities remains unclear.
Yongfeng Zhu   +9 more
wiley   +1 more source

Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Stomach: A Case Report in a 52‐Year‐Old Male Following Total D2 Gastrectomy

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Gastric MANEC (gMANEC) is a rare tumor composed of at least 30% each adenocarcinoma and neuroendocrine carcinoma (NEC) components. A 52‐year‐old male underwent total D2 gastrectomy for gastric cancer. Final pathology revealed MANEC. We compare outcomes and mortality rates between gastric MANEC and conventional adenocarcinoma.
Paraskeva Aikaterini   +1 more
wiley   +1 more source

Carcinosarcoma of the Parotid With Osteosarcoma Component: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Carcinosarcomas of the salivary gland with osteosarcoma component are very rare, with only 17 cases reported. Despite multiple poor prognostic factors, our patient's outcome was favorable, highlighting the importance of early diagnosis and aggressive treatment in improving prognosis for this aggressive tumor variant.
Shubham Dokania   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy